Cargando…
A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies
The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and utilized it to conduct a pan-cancer analysis of oncogenic NRF2 signaling. We identified an immunoe...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011429/ https://www.ncbi.nlm.nih.gov/pubmed/36867945 http://dx.doi.org/10.1016/j.redox.2023.102644 |
_version_ | 1784906390895067136 |
---|---|
author | Härkönen, Jouni Pölönen, Petri Deen, Ashik Jawahar Selvarajan, Ilakya Teppo, Hanna-Riikka Dimova, Elitsa Y. Kietzmann, Thomas Ahtiainen, Maarit Väyrynen, Juha P. Väyrynen, Sara A. Elomaa, Hanna Tynkkynen, Niko Eklund, Tiia Kuopio, Teijo Talvitie, Eva-Maria Taimen, Pekka Kallajoki, Markku Kaikkonen, Minna U. Heinäniemi, Merja Levonen, Anna-Liisa |
author_facet | Härkönen, Jouni Pölönen, Petri Deen, Ashik Jawahar Selvarajan, Ilakya Teppo, Hanna-Riikka Dimova, Elitsa Y. Kietzmann, Thomas Ahtiainen, Maarit Väyrynen, Juha P. Väyrynen, Sara A. Elomaa, Hanna Tynkkynen, Niko Eklund, Tiia Kuopio, Teijo Talvitie, Eva-Maria Taimen, Pekka Kallajoki, Markku Kaikkonen, Minna U. Heinäniemi, Merja Levonen, Anna-Liisa |
author_sort | Härkönen, Jouni |
collection | PubMed |
description | The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and utilized it to conduct a pan-cancer analysis of oncogenic NRF2 signaling. We identified an immunoevasive phenotype where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression and T cell and macrophage infiltration in squamous malignancies of the lung, head and neck area, cervix and esophagus. Squamous NRF2 overactive tumors comprise a molecular phenotype with SOX2/TP63 amplification, TP53 mutation and CDKN2A loss. These immune cold NRF2 hyperactive diseases are associated with upregulation of immunomodulatory NAMPT, WNT5A, SPP1, SLC7A11, SLC2A1 and PD-L1. Based on our functional genomics analyses, these genes represent candidate NRF2 targets, suggesting direct modulation of the tumor immune milieu. Single-cell mRNA data shows that cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands, and increased expression of immunosuppressive ligands NAMPT, SPP1 and WNT5A that mediate signaling in intercellular crosstalk. In addition, we discovered that the negative relationship of NRF2 and immune cells are explained by stromal populations of lung squamous cell carcinoma, and this effect spans multiple squamous malignancies based on our molecular subtyping and deconvolution data. |
format | Online Article Text |
id | pubmed-10011429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-100114292023-03-15 A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies Härkönen, Jouni Pölönen, Petri Deen, Ashik Jawahar Selvarajan, Ilakya Teppo, Hanna-Riikka Dimova, Elitsa Y. Kietzmann, Thomas Ahtiainen, Maarit Väyrynen, Juha P. Väyrynen, Sara A. Elomaa, Hanna Tynkkynen, Niko Eklund, Tiia Kuopio, Teijo Talvitie, Eva-Maria Taimen, Pekka Kallajoki, Markku Kaikkonen, Minna U. Heinäniemi, Merja Levonen, Anna-Liisa Redox Biol Research Paper The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and utilized it to conduct a pan-cancer analysis of oncogenic NRF2 signaling. We identified an immunoevasive phenotype where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression and T cell and macrophage infiltration in squamous malignancies of the lung, head and neck area, cervix and esophagus. Squamous NRF2 overactive tumors comprise a molecular phenotype with SOX2/TP63 amplification, TP53 mutation and CDKN2A loss. These immune cold NRF2 hyperactive diseases are associated with upregulation of immunomodulatory NAMPT, WNT5A, SPP1, SLC7A11, SLC2A1 and PD-L1. Based on our functional genomics analyses, these genes represent candidate NRF2 targets, suggesting direct modulation of the tumor immune milieu. Single-cell mRNA data shows that cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands, and increased expression of immunosuppressive ligands NAMPT, SPP1 and WNT5A that mediate signaling in intercellular crosstalk. In addition, we discovered that the negative relationship of NRF2 and immune cells are explained by stromal populations of lung squamous cell carcinoma, and this effect spans multiple squamous malignancies based on our molecular subtyping and deconvolution data. Elsevier 2023-02-27 /pmc/articles/PMC10011429/ /pubmed/36867945 http://dx.doi.org/10.1016/j.redox.2023.102644 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Härkönen, Jouni Pölönen, Petri Deen, Ashik Jawahar Selvarajan, Ilakya Teppo, Hanna-Riikka Dimova, Elitsa Y. Kietzmann, Thomas Ahtiainen, Maarit Väyrynen, Juha P. Väyrynen, Sara A. Elomaa, Hanna Tynkkynen, Niko Eklund, Tiia Kuopio, Teijo Talvitie, Eva-Maria Taimen, Pekka Kallajoki, Markku Kaikkonen, Minna U. Heinäniemi, Merja Levonen, Anna-Liisa A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies |
title | A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies |
title_full | A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies |
title_fullStr | A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies |
title_full_unstemmed | A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies |
title_short | A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies |
title_sort | pan-cancer analysis shows immunoevasive characteristics in nrf2 hyperactive squamous malignancies |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011429/ https://www.ncbi.nlm.nih.gov/pubmed/36867945 http://dx.doi.org/10.1016/j.redox.2023.102644 |
work_keys_str_mv | AT harkonenjouni apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT polonenpetri apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT deenashikjawahar apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT selvarajanilakya apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT teppohannariikka apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT dimovaelitsay apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT kietzmannthomas apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT ahtiainenmaarit apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT vayrynenjuhap apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT vayrynensaraa apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT elomaahanna apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT tynkkynenniko apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT eklundtiia apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT kuopioteijo apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT talvitieevamaria apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT taimenpekka apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT kallajokimarkku apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT kaikkonenminnau apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT heinaniemimerja apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT levonenannaliisa apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT harkonenjouni pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT polonenpetri pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT deenashikjawahar pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT selvarajanilakya pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT teppohannariikka pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT dimovaelitsay pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT kietzmannthomas pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT ahtiainenmaarit pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT vayrynenjuhap pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT vayrynensaraa pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT elomaahanna pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT tynkkynenniko pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT eklundtiia pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT kuopioteijo pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT talvitieevamaria pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT taimenpekka pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT kallajokimarkku pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT kaikkonenminnau pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT heinaniemimerja pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies AT levonenannaliisa pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies |